Hi fellow flowers, We are in a cost containment environment and are currently evaluating changing our leukemia/lymphoma panel to utilize all Caltag monoclonal antibodies. The clones of interest are CD20, CD5, CD7, CD3, CD4, CD8, CD10, CD19, CD25, CD11c, CD16, CD56, CD14, CD23, with CD45(cy5 tandem). Since it is inherently difficult to properly evaluate these clones on "live" specimens, does anyone have any experience with them? I am particularly interested in their performance characteristics, and how well they match their appropriate isotypic controls. Other than using "live" specimens what is the best way for someone to avoid the pitfalls of a major change in monoclonal antibody suppliers? Any input would be greatly appreciated. Thank you. Rex E. Hensley, GS-12, DAF Technical Supervisor Cellular Immunology Wilford Hall Medical Center Lackland AFB, Texas hensley@whmc-lafb.af.mil
This archive was generated by hypermail 2b29 : Wed Apr 03 2002 - 11:49:43 EST